- Home
- ACU vs MCRB Comparison
ACU vs MCRB Comparison
Compare ACU & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACU
- MCRB
- Stock Information
- Founded
- ACU 1867
- MCRB 2010
- Country
- ACU United States
- MCRB United States
- Employees
- ACU N/A
- MCRB N/A
- Industry
- ACU Industrial Machinery/Components
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- ACU Consumer Discretionary
- MCRB Health Care
- Exchange
- ACU Nasdaq
- MCRB Nasdaq
- Market Cap
- ACU 145.9M
- MCRB 144.6M
- IPO Year
- ACU N/A
- MCRB 2015
- Fundamental
- Price
- ACU $38.23
- MCRB $19.60
- Analyst Decision
- ACU
- MCRB Hold
- Analyst Count
- ACU 0
- MCRB 4
- Target Price
- ACU N/A
- MCRB $14.33
- AVG Volume (30 Days)
- ACU 12.2K
- MCRB 129.8K
- Earning Date
- ACU 10-21-2025
- MCRB 11-12-2025
- Dividend Yield
- ACU 1.67%
- MCRB N/A
- EPS Growth
- ACU N/A
- MCRB N/A
- EPS
- ACU 2.55
- MCRB 10.22
- Revenue
- ACU $194,061,991.00
- MCRB N/A
- Revenue This Year
- ACU $2.85
- MCRB N/A
- Revenue Next Year
- ACU $4.16
- MCRB N/A
- P/E Ratio
- ACU $15.07
- MCRB $1.89
- Revenue Growth
- ACU 0.70
- MCRB N/A
- 52 Week Low
- ACU $34.35
- MCRB $6.53
- 52 Week High
- ACU $45.42
- MCRB $24.67
- Technical
- Relative Strength Index (RSI)
- ACU 35.28
- MCRB 53.32
- Support Level
- ACU $37.81
- MCRB $19.17
- Resistance Level
- ACU $38.85
- MCRB $20.85
- Average True Range (ATR)
- ACU 0.97
- MCRB 1.31
- MACD
- ACU -0.21
- MCRB -0.12
- Stochastic Oscillator
- ACU 11.17
- MCRB 37.49
About ACU Acme United Corporation.
Acme United Corp is a supplier of first aid and medical products and cutting technology to the school, home, office, hardware, sporting goods, and industrial markets. Its principal products sold across all segments are first aid kits and medical products, scissors, shears, knives, rulers, pencil sharpeners, and sharpening tools. The Company sells its products to mass market and e-commerce retailers, industrial distributors, wholesale, contract, and retail stationery distributors, office supply superstores, sporting goods stores, and hardware chains. The Company's reportable business segments consist of the United States, Canada, and Europe, out of which the majority of the company's revenue is derived from the United States.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.